These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 5052323

  • 1. [Treatment of Parkinson's disease with L-dopa alone or combined with Ro 4-4602].
    Barbeau A, Gillo-Joffroy L, Mars H, Arsenault A.
    Rev Can Biol; 1972; 31():Suppl:169-74. PubMed ID: 5052323
    [No Abstract] [Full Text] [Related]

  • 2. Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease.
    Barbeau A, Mars H, Botez MI, Joubert M.
    Can Med Assoc J; 1972 Jun 10; 106(11):1169-74. PubMed ID: 5034697
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Levodopa and Ro 4-4602 in psoriasis.
    Giroux JM, Dubuc R, Barbeau A.
    Lancet; 1972 Aug 12; 2(7772):333-4. PubMed ID: 4115065
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R, de Ajuriaguerra J.
    Nouv Presse Med; 1973 Feb 03; 2(5):315-6. PubMed ID: 4686226
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. On the mechanism of the nullification of CNS effects of L-DOPA by pyridoxine in Parkinsonian patients.
    Pfeiffer R, Ebadi M.
    J Neurochem; 1972 Sep 03; 19(9):2175-81. PubMed ID: 5072392
    [No Abstract] [Full Text] [Related]

  • 11. [Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
    Lombardo L, de la Garza R, Ivan-Reynoso G.
    Arch Invest Med (Mex); 1974 Sep 03; 5(2):105-16. PubMed ID: 4433198
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Therapy of Parkinson's syndrome with L-dopa per os combined with a decarboxylase inhibitor (Ro 46.02)].
    Tissot R, Gaillard JM, Guggisberg M, Gauthier G, De Ajuriaguerra J.
    Neurol Neurocir Psiquiatr; 1969 Sep 03; 10(1):1-25. PubMed ID: 5406970
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ro 4-4602 and levodopa in the treatment of Parkinsonism.
    Miller EM, Wiener L.
    Neurology; 1974 May 03; 24(5):482-6. PubMed ID: 4857107
    [No Abstract] [Full Text] [Related]

  • 16. Treatment of Parkinson's disease with levodopa and Ro 4-4602.
    Barbeau A, Gillo-Joffroy L, Mars H.
    Clin Pharmacol Ther; 1971 May 03; 12(2):353-9. PubMed ID: 4930866
    [No Abstract] [Full Text] [Related]

  • 17. Treatment of Parkinsonism with L-dopa and decarboxylase inhibitors. An electrophysiological study.
    Dietrichson P.
    Acta Neurol Scand Suppl; 1972 May 03; 51():111-3. PubMed ID: 4514333
    [No Abstract] [Full Text] [Related]

  • 18. The role of a dihydromorphanthridine derivative in Parkinson's patients treated with L-dopa. A preliminary report.
    Wycis HT.
    Confin Neurol; 1972 May 03; 34(2):130-5. PubMed ID: 4666056
    [No Abstract] [Full Text] [Related]

  • 19. Treatment of Parkinson's disease with L-DOPA and an association L-DOPA plus a DOPA decarboxylase inhibitor.
    Fazio C, Agnoli A, Casacchia M, Reitano M, Ruggieri S, Barba C, Volante F.
    Z Neurol; 1972 May 03; 202(4):347-55. PubMed ID: 4117654
    [No Abstract] [Full Text] [Related]

  • 20. [Comparison of the effect of L-Dopa and of an L-Dopa+decarboxylase inhibitor combination in Parkinson's disease].
    Schneider E, Fischer PA, Jacobi P, Maxion H.
    Arch Psychiatr Nervenkr (1970); 1973 Mar 19; 217(1):95-112. PubMed ID: 4695662
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.